Related Experiment Video
Updated: Mar 13, 2026
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.9K
Bifeprunox versus placebo for schizophrenia.
Arka Chattopadhyay1, Stephen Frey, Ghiselle Green
1Medical School, University of Nottingham, 6 Rolleston Drive, Nottingham, UK, NG7 1JT.
The Cochrane Database of Systematic Reviews
|October 13, 2016
Summary
Bifeprunox showed some positive effects in treating schizophrenia symptoms, but data quality was low. Limited evidence suggests potential benefits, though concerns remain due to incomplete trial data.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Bifeprunox, an antipsychotic, faced market rejection by the FDA in 2009 due to insufficient evidence of efficacy and safety concerns.
- Further research was required to demonstrate bifeprunox's effectiveness beyond existing treatments for schizophrenia.
Purpose of the Study:
- To investigate the clinical and adverse effects of bifeprunox in individuals diagnosed with schizophrenia.
Main Methods:
- A systematic review of randomized controlled trials (RCTs) comparing bifeprunox to placebo for schizophrenia.
- Data extraction and analysis included risk ratios and mean differences, with a random-effects model and GRADE assessment for bias and evidence quality.
Main Results:
- Four RCTs were included, revealing low-quality evidence of bifeprunox (20 mg) reducing positive and negative symptoms of schizophrenia.
- A statistically significant improvement in deterioration was observed with bifeprunox, though based on very low-quality evidence.
- Weight gain was comparable between bifeprunox and placebo groups; no data on quality of life or economic outcomes were available.
Conclusions:
- Bifeprunox demonstrated some positive clinical effects and a favorable adverse event profile, but the overall evidence quality was low.
- Incomplete and inaccessible trial data from the FDA and pharmaceutical companies hinder a full evaluation of bifeprunox's efficacy and safety.
- Lack of data transparency raises questions about the fulfillment of obligations to patients with schizophrenia and their clinicians.
More Related Videos
08:32Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
23.5K
09:14Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging
Published on: March 14, 2025
1.2K
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
649
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
649
01:28Psychosis and Antipsychotic Drugs: Overview
1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:29Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:28Drug Therapy
364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
364